Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus MESTINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus MESTINON.
DONEPEZIL HYDROCHLORIDE vs MESTINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor